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Significance {#sec1}
============

**We identified persistent hepatocyte apoptosis as a universally decisive determinant of HCC development in distinct mouse models and various human CLDs. Accordingly, levels of hepatocyte apoptosis and DNA damage predict the risk for liver cancer, the second leading cause of cancer-related death worldwide. Finding that caspase-8 not only executes hepatocyte apoptosis, but also has a non-apoptotic function in DNA damage response demonstrates its opposing functions. By orchestrating DNA damage response as part of the signaling platform, caspase-8 may protect against proliferation-associated genetic instability, and therefore early stages of hepatocarcinogenesis. Whereas once tumors are established, low caspase-8 expression is associated with less aggressive behavior of human HCC. Our data illustrate diverging mechanistic links of caspase-8 to cancer biology.**

Introduction {#sec2}
============

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor, the fifth most prevalent cancer, the second leading cause of cancer-related death and the fastest rising cancer worldwide ([@bib11]). HCC arises on the background of chronic liver diseases (CLDs) such as chronic hepatitis B virus and hepatitis C virus (HCV) infections, alcohol, metabolically and dietary-induced fatty liver disease, and steatohepatitis, autoimmune, or chronic cholestatic diseases ([@bib13]). Independent of the underlying etiology, all CLDs exhibit persistent hepatocyte damage. To maintain liver homeostasis and prevent the accumulation of mutations, damaged hepatocytes are eliminated by programmed cell death, regulated by key molecules, including caspase-8 and receptor-interacting protein kinase 1 (RIPK1) ([@bib28]). Hepatocyte-specific knock out of the anti-apoptotic Bcl2-family member myeloid cell leukemia 1 (Mcl-1) gene in mice (Mcl-1^Δhep^ mice) recapitulates CLD pathophysiology including severe liver damage and regeneration early in life ([@bib44]) and subsequent HCC development ([@bib46]). Here we functionally and quantitatively examine the interplay between caspase-8-dependent hepatocyte apoptosis and regeneration-associated replication stress, genetic instability, and hepatocarcinogenesis. Moreover, we investigate a role for caspase-8, in conjunction with other regulators of cell death and inflammation, during DNA damage recognition within hepatocytes.

Results {#sec3}
=======

CLDs Display High Levels of Hepatocyte Apoptosis, DNA Damage, Genetic Instability, and Risk for HCC {#sec3.1}
---------------------------------------------------------------------------------------------------

Hepatocyte apoptosis is an etiology-independent hallmark of human CLDs ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). Increased levels of apoptosis correlated with increased hepatocyte proliferation, reflecting regeneration, with significantly higher numbers of cells positive for the DNA damage marker γH2AX ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}A, and S1C--S1F), and with higher expression of DNA damage-responsive (DDR) genes ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Liver tissues from CLD patients further displayed high levels of genetic instability at chromosomal common fragile sites (CFS) ([@bib14]) as determined by TaqMan copy number assay ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}G) and fragment length analysis ([Figure 1](#fig1){ref-type="fig"}C). Thus, our data suggest that genetic instability is established long before dysplastic changes are detectable. We next looked for an association between serum transaminase levels ([Figure 1](#fig1){ref-type="fig"}D) (as a surrogate marker for liver cell apoptosis) and subsequent HCC development. Elevated serum alanine and aspartate transaminase (ALT and AST) levels in CLDs were associated with subsequent HCC development: (1) retrospective analysis of patients with chronic HCV infection revealed that patients who developed HCC had significantly higher ALT and AST levels (p \< 0.05) during a period of 6 years preceding HCC diagnosis compared with HCC-free individuals of the same cohort (matched for model of end-stage liver disease) score with similar albumin and bilirubin levels ([Figures 1](#fig1){ref-type="fig"}E, 1F, and [S1](#mmc1){ref-type="supplementary-material"}H). (2) Retrospective analysis of liver transplant (LT) patients revealed that patients transplanted for HCC had significantly higher ALT and AST levels 1 year prior to LT compared with patients of the same cohort undergoing LT for non-HCC indications (p \< 0.001; [Figure S1](#mmc1){ref-type="supplementary-material"}I).Figure 1DNA Damage and Genetic Instability CLDs Preceding Neoplastic Lesions and HCC(A) Apoptosis (cl.Casp3), proliferation (Ki67), and DNA damage (γH2AX) in human CLDs of different etiology (viral hepatitis: hepatitis B virus \[HBV\] and \[HCV\], metabolic \[NASH\], and autoimmune \[AIH\] diseases). Arrowheads indicate cells with positive IHC staining. Scale bars, 100 μm.(B) TaqMan copy number assay for allelic imbalances (AI). Each square represents one area of microdissected tissue, lines indicate different areas of the same liver (red, AI; black, no AI; NT, non-tumor CLD tissue).(C) Fragment length analysis (loci DS31263 and DS31289) in CLD tissues. Arrowheads indicate changes in fragment length distribution.(D) Serum ALT levels in CLDs (n = 4 HBV, n = 8 HCV, n = 4 NASH, and n = 4 AIH).(E and F) Serum ALT levels in patients with HCC versus without HCC of the same cohort (n = 13 in both groups). (E) Time course 6 years prior to diagnosis and (F) mean of ALT values over time.In (D), (E), and (F), data are presented as mean ± SEM. Statistical significance was calculated using Fisher\'s exact test (B), ANOVA with Bonferroni correction (D), or Student\'s t test (E and F). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Risk for HCC Development Correlates with Levels of Hepatocyte Apoptosis and DNA Damage Also in Mice {#sec3.2}
---------------------------------------------------------------------------------------------------

To functionally investigate the role of apoptosis for HCC development *in vivo*, we prospectively monitored Mcl-1^Δhep^ mice for serum transaminase levels which, similarly to CLD patients, are characterized by chronically increased hepatocyte apoptosis and regeneration ([@bib44]). Remarkably, the same Mcl-1^Δhep^ mice that developed liver tumors at 1 year (50% of this cohort) also displayed higher serum ALT (and AST, data not shown) levels throughout life compared with Mcl-1^Δhep^ mice without tumor development ([Figures 2](#fig2){ref-type="fig"}A--2C). Parallel to a reduced sensitivity toward tumor necrosis factor (TNF)-mediated apoptotic signaling with age ([Figure S2](#mmc1){ref-type="supplementary-material"}A), ALT levels dropped and reached similar levels in both groups after 4 months. Nevertheless, differences were statistically significant at 2 and 4 months, i.e., the period of high levels of liver damage and regeneration. Livers of 2-month-old Mcl-1^Δhep^ mice showed a moderate to high disease activity when applying a standard human scoring system ([@bib4]) ([Figure 2](#fig2){ref-type="fig"}D). A statistically significant positive correlation between the percentage of cleaved caspase-3^+^ hepatocytes and serum ALT levels was also found ([Figure 2](#fig2){ref-type="fig"}E). Livers of 2-month-old Mcl-1^Δhep^ mice revealed increased levels of proliferating hepatocytes and numbers of γH2AX^+^ hepatocytes ([Figures 2](#fig2){ref-type="fig"}F and 2G), which positively correlated with ALT levels ([Figure 2](#fig2){ref-type="fig"}H), strongly suggesting a link between hepatocyte apoptosis and DNA damage.Figure 2Risk of HCC Development Correlates with Apoptosis and DNA Damage in Mcl-1^Δhep^ Mice(A) Livers from 12-month-old mice. Arrowheads indicate a tumor. Scale bar, 1 cm.(B) Serum ALT levels throughout life time of wild-type mice, Mcl-1^Δhep^ mice that developed HCC at 12 months (n = 12), and Mcl-1^Δhep^ mice that did not.(C) Serum ALT levels at 2 months (n = 8 animals per group).(D) Hepatocyte death rates (n = 20).(E) Correlation of ALT levels with hepatocytes apoptosis (n = 15).(F) Hepatocyte mitosis (upper square and insert), apoptosis (lower square and insert), and signs of DNA damage (γH2AX, black arrow) in livers of Mcl-1^Δhep^ mice. Scale bars, 50 μm.(G) γH2AX^+^ hepatocytes per high-power field (HPF) in wild-type (n = 7) and Mcl-1^Δhep^ mice (n = 12).(H) Correlation of ALT levels with the number of γH2AX^+^ hepatocytes (n = 11).(I) Pie chart displaying the percentage of genes at least 2-fold upregulated in Mcl-1^Δhep^ mice and clustered according to KEGG pathway database analysis.(J) Gene set enrichment analysis comparing all differentially regulated genes from Mcl-1^Δhep^ mice with various gene sets. NES, normalized enrichment score.In (B) and (C), data are presented as mean ± SEM. In (G), the bar indicates the mean. Statistical significance was calculated using Student\'s t test (B and G), ANOVA with Bonferroni correction (C). ^∗^p \< 0.05. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Next, mRNA profiling unraveled genes differentially expressed in livers of 2-month-old wild-type, homozygous, and hemizygous Mcl-1^Δhep^ mice, which were verified by qPCR ([Figure S2](#mmc1){ref-type="supplementary-material"}B). KEGG pathway analysis revealed that genes upregulated by at least 2-fold were involved in diverse cellular functions including apoptosis, cell cycle, differentiation, metabolism, and DDR ([Figure 2](#fig2){ref-type="fig"}I). Gene set enrichment analysis revealed that livers of Mcl-1^Δhep^ mice were not only significantly enriched for genes related to apoptosis and proliferation, but also to viral infection, wounding (not shown), alcoholic hepatitis, and, despite being non-neoplastic, also to HCC ([Figure 2](#fig2){ref-type="fig"}J). Collectively, our findings show that Mcl-1^Δhep^ mice are appropriate for investigating HCC development on a CLD background.

Next, we tested whether increased hepatocyte apoptosis through tumor necrosis factor receptor 1 (TNFR1) per se determined hepatocarcinogenesis in Mcl-1^Δhep^ mice, rather than loss of a non-apoptotic function of Mcl-1. Mcl-1^Δhep^ mice were crossed with TNFR1-deficient mice (Mcl-1^Δhep^/TNFR1^−/−^ mice) to inhibit TNFR1-dependent apoptosis and downstream signaling via TNFR-caspase-8-BID/tBID-Mcl-1. Two-month-old Mcl-1^Δhep^/TNFR1^−/−^ mice showed lower serum transaminase activity compared with age-matched Mcl-1^Δhep^ mice ([Figure 3](#fig3){ref-type="fig"}A), and revealed significantly lower numbers of apoptotic and proliferating hepatocytes compared with Mcl-1^Δhep^ mice ([Figure 3](#fig3){ref-type="fig"}B). This was paralleled by significantly increased hepatic mRNA levels of the death receptors *Tnfr1* and *Fas* in Mcl-1^Δhep^ mice compared with Mcl-1^Δhep^/TNFR1^−/−^ mice, whereas *Tnfr2*, *Trailr*, and the ligands *Tnfa*, *Fasl*, and *Trail* ([Figure S3](#mmc1){ref-type="supplementary-material"}A), and bilirubin and alkaline phosphatase showed no statistically significant difference ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Interestingly, livers of Mcl-1^Δhep^ mice, but not Mcl-1^Δhep^/TNFR1^−/−^ mice, displayed substantial caspase-8 cleavage ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Similar to LPS/DGal-challenged wild-type mice treated with the caspase-8 inhibitor zITED ([Figure S3](#mmc1){ref-type="supplementary-material"}E), Mcl-1^Δhep^ mice treated with zITED also displayed significantly decreased ALT levels (and AST, data not shown) and significantly less hepatocyte apoptosis ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G). In contrast, treating Mcl-1^Δhep^ mice with the caspase-1 inhibitor, YVAD-CMK, used as an off-target control for zITED, did not affect ALT levels ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Thus, hepatocyte apoptosis in Mcl-1^Δhep^ mice was caspase-8 dependent. Remarkably, Mcl-1^Δhep^/TNFR1^−/−^ mice demonstrated a significantly reduced tumor incidence at 1 year compared with Mcl-1^Δhep^ mice (28% versus 50%, p \< 0.05; [Figures 3](#fig3){ref-type="fig"}C and 3D). In line with the data presented above, those Mcl-1^Δhep^/TNFR1^−/−^ mice that developed liver tumors also displayed significantly higher transaminase levels at 2 months ([Figure 3](#fig3){ref-type="fig"}E).Figure 3Reduced Apoptosis, Proliferation, and Tumor Development in Mcl-1^Δhep^/TNFR1^−/−^ Mice(A) AST and ALT levels from 2-month-old Mcl-1^Δhep^ (n = 16), Mcl-1/TNFR1^−/−^ (n = 10), and wild-type (n = 8) mice.(B) Staining and quantification for H&E, cl.Casp3, and Ki67 in 2-month-old wild-type, Mcl-1^Δhep^/TNFR1^−/−^, and Mcl-1^Δhep^ mice. Arrowheads indicate cells with positive IHC staining. Scale bars, 100 μm.(C) Macroscopy, H&E, and collagen IV staining of livers at 12 months of age. The arrowhead indicates a tumor. Scale bars, 100 μm.(D) Tumor development after 12 months in Mcl-1^Δhep^ mice (n = 44) compared with Mcl-1^Δhep^/TNFR1^−/−^ mice (n = 39).(E) Retrospective analysis of tumor development and correlation to ALT levels in the serum of 2-month-old mice (n = 11 Mcl-1^Δhep^/TNFR1^−/−^ mice without HCC, n = 5 with HCC).In (A), (B), (D), and (E), data are presented as mean ± SEM. Statistical significance was calculated using Student\'s t test (A and B), ANOVA with Bonferroni correction (E), or Fisher\'s exact test (D). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; n.s., not significant. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Further analyses of the microenvironment of Mcl-1^Δhep^ livers revealed: (1) no activation of canonical nuclear factor κB (NF-κB) signaling ([Figure S3](#mmc1){ref-type="supplementary-material"}H), (2), no or only low levels of inflammasome activation as determined by cleaved caspase-1 and cleaved interleukin-1β (IL-1β) levels ([Figure S3](#mmc1){ref-type="supplementary-material"}I and data not shown), and (3) a significant increase expression of several inflammatory cytokines *IL6*, *IL33*, and *IFNγ* (with reduced levels of *IL6*, *IL33*, and *IFNγ* in Mcl-1^Δhep^/TNFR1^−/−^ livers; [Figure S3](#mmc1){ref-type="supplementary-material"}J).

Collectively, these findings show that the association between high apoptotic activity of hepatocytes (in early disease stages) with subsequent liver cancer development previously described for CLD patients also exists in Mcl-1^Δhep^ mice. Furthermore, they suggest that persistently increased hepatocyte apoptosis, resulting in regenerative proliferation and high DNA replication rate, determines hepatocarcinogenesis. This hypothesis is underpinned by stochastic considerations ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Reduced DNA Damage and Genetic Instability upon Ablation of TNFR1 and Caspase-8 {#sec3.3}
-------------------------------------------------------------------------------

To identify the source of DNA damage and to determine the level of genetic instability in relation to hepatocyte apoptosis, we analyzed Mcl-1^Δhep^ mice, and, to exclude Mcl-1-specific effects, TAK1^Δhep^ mice characterized by increased hepatocyte apoptosis at 6 weeks and caspase-8-dependent HCC development at 35 weeks (100% incidence) ([@bib5]). Co-staining for γH2AX and cleaved caspase-3 revealed that hepatocytes from 6- to 8-week-old Mcl-1^Δhep^ mice as well as TAK1^Δhep^ mice which were positive for γH2AX were mostly negative for cleaved caspase-3. Thus, γH2AX-positivity was unlikely to be a consequence of apoptosis of individual hepatocytes ([Figure 4](#fig4){ref-type="fig"}A). Immunofluorescence (IF) staining for γH2AX and Ki67 of livers from 6- to 8-week-old mice revealed virtually no γH2AX^+^ hepatocytes in wild-type livers, whereas Mcl-1^Δhep^ and TAK1^Δhep^ hepatocytes displayed the typical nuclear staining pattern and substantial γH2AX/Ki67 double positivity (∼10% and 20%, respectively; [Figures 4](#fig4){ref-type="fig"}B and 4C).Figure 4Reduced DNA Damage And Genetic Instability in Mcl-1^Δhep^/TNFR1^−/−^ and TAK1/Casp8^Δhep^ Mice and Intercrossings(A) Staining for γH2AX (black) and cleaved Casp3 (red), double-positive hepatocytes (black/red arrows). Scale bar, 50 μm.(B) IF staining for γH2AX and Ki67 in wild-type, Mcl-1^Δhep^, and Mcl-1^Δhep^/TNFR1^−/−^ mice, as well as TAK1^Δhep^, TAK1/Casp8^Δhep^, and TAK1^Δhep^/RIPK3^−/−^ mice. Arrowheads indicate cells with positive IF staining. Scale bar, 10 μm.(C) Quantification of Ki67^+^ and Ki67^+^/γH2AX^+^ hepatocytes (n = 4 mice per group, n = 5 for Mcl-1^Δhep^ mice).(D) Rate of AI in wild-type, Mcl-1^Δhep^, and Mcl-1^Δhep^/TNFR1^−/−^ mice, TAK1^Δhep^, TAK1^Δhep^/RIPK3^−/−^, and TAK1/Casp8^Δhep^ mice (TaqMan copy number assay, each square represents one area of microdissected liver tissue, lines indicate different areas of the same liver; red, AI; black, no AI). Mcl-1^Δhep^ mice and intercrossings at 2 months; TAK1^Δhep^ mice and intercrossings at 6 weeks of age.In (C), data are presented as mean ± SEM. Statistical significance was calculated using ANOVA with Bonferroni correction (C), or Fisher\'s exact test (D). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To further investigate hepatocyte apoptosis, DDR, and genetic instability in relation to hepatocarcinogenesis, Mcl-1^Δhep^/TNFR1^−/−^ mice and crossings of TAK1^Δhep^ mice were analyzed: TAK1^Δhep^/RIPK3^−/−^ mice (devoid of necroptosis, HCC-prone), and TAK1^Δhep^/Casp8^Δhep^ mice (devoid of apoptosis, not HCC-prone; [Table S1](#mmc1){ref-type="supplementary-material"}) ([@bib45]). The percentage of Ki67^+^/γH2AX^+^ hepatocytes was significantly reduced in intercrossings with reduced apoptosis (Mcl-1^Δhep^/TNFR1^−/−^ \< Mcl-1^Δhep^ mice; and TAK1^Δhep^/Casp8^Δhep^ \< TAK1^Δhep^ \< TAK1^Δhep^/RIPK3^−/−^ mice, respectively; [Figures 4](#fig4){ref-type="fig"}B and 4C). Similarly, intercrossings with increased HCC burden also displayed an increased percentage of Ki67^+^/γH2AX^+^ hepatocytes (Mcl-1^Δhep^ \> Mcl-1^Δhep^/TNFR1^−/−^ mice; and TAK1^Δhep^/RIPK3^−/−^ \> TAK1^Δhep^/Casp8^Δhep^ \> TAK1^Δhep^ mice, respectively; [Figures 4](#fig4){ref-type="fig"}B and 4C). The activation of DNA repair pathways in regenerative murine livers was further corroborated by western blot analysis and expression analysis of genes related to DNA replication, DDR, and DNA repair. Again, mRNA expression of DDR-related genes (and associated protein modifications) were reduced in parallel with hepatocyte apoptosis levels ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). In contrast to wild-type mice, livers of Mcl-1^Δhep^, TAK1^Δhep^, and TAK1^Δhep^/RIPK3^−/−^ mice showed widespread allelic imbalances (AI) at CFS, demonstrating genetic instability in hyper-apoptotic and hyper-proliferative mouse livers. Of note, although higher compared with wild-type mice, AI rates were much lower in Mcl-1^Δhep^/TNFR1^−/−^ mice and TAK1^Δhep^/Casp8^Δhep^ mice ([Figure 4](#fig4){ref-type="fig"}D).

Since almost all γH2AX^+^ hepatocytes were proliferating (Ki67+), replication stress (single-stranded DNA breaks accumulation and replication fork stalling) was considered the most likely source of DNA damage ([@bib17]). This was corroborated by fluorescence-activated cell-sorting analysis showing significantly less γH2AX+/RPA^+^ hepatocytes in low proliferating livers ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Treating Mcl-1^Δhep^ and TAK1^Δhep^ mice with the antioxidants, butylated hydroxyanisole or vitamin E, for 4 weeks revealed no evidence for reactive oxygen species being a major inducer of DNA damage in these mice ([Figures S5](#mmc1){ref-type="supplementary-material"}E--S5H).

Hyper-proliferation-Associated Replicative Stress in Regenerating Livers Causes DNA Damage {#sec3.4}
------------------------------------------------------------------------------------------

Next, to test whether proliferation by itself, i.e., independent of hepatocyte apoptosis, was sufficient to trigger DNA damage, we performed partial hepatectomy (PHX). Whereas low levels of baseline proliferation in wild-type mice were not associated with detectable levels of DNA damage, western blot analysis and immunohistochemistry for γH2AX peaked at 48 hr post-PHX, i.e., long after evidence for apoptosis ([@bib39]), and parallel to the proliferative activity ([Figures 5](#fig5){ref-type="fig"}A--5G). The correlation between hepatic hyper-proliferation and DNA damage was confirmed by γH2AX/bromodeoxyuridine (BrdU) double staining. Almost all γH2AX^+^ hepatocytes had incorporated BrdU, indicating that DNA damage occurred in replicating hepatocytes. To further investigate whether γH2AX in proliferating hepatocytes was marking DNA breakage, beside replication stress per se, pulse field gel electrophoresis (PFGE) was performed showing DNA double-strand breaks (DSB) in livers 48 hr after PHX ([Figure 5](#fig5){ref-type="fig"}F).Figure 5Detection of Proliferation-Associated DNA Damage after PHX Is Impaired in Casp8^Δhep^ Mice(A--C) Western blot analysis of whole-liver lysates (A), immunostainings (B), and quantification of γH2AX^+^ hepatocytes 0, 6, 24, and 48 hr post-PHX (C). Scale bar, 50 μm.(D and E) BrdU incorporation combined with γH2AX staining (n = 4). Scale bar, 10 μm.(F and G) PFGE with densitometric quantification to visualize DNA DSB in livers of wild-type mice after PHX (n = 3).(H and I) IF staining (H) and quantification of Ki67^+^/γH2AX^+^ hepatocytes in wild-type, TNFR1/2^−/−^, RIPK3^−/−^, and Casp8^Δhep^ mice (I). Arrowheads indicate cells with positive IF staining. Scale bar, 10 μm.(J and K) PFGE with densitometric quantification to visualize DNA DSB in livers of Casp8^Δhep^ mice after PHX.In (C), bar represents mean. In (E), (G), (I), and (K) data are presented as mean ± SEM. In (G), bar indicates the mean. Statistical significance was calculated using ANOVA with Bonferroni correction (C and I) or Student\'s t test (E, G, and K). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; n.s., not significant. Irrelevant bands were omitted from gels (F and J). Areas in which lanes were omitted are indicated by white space between lanes. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To test if hyper-proliferation-associated replication stress also occurs in human livers, biopsies of patients after ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) procedure were analyzed ([@bib35]). Biopsies taken post-liver partition and portal vein ligation from the patients\' highly regenerating left lobe revealed significantly elevated numbers of Ki67^+^ hepatocytes and a substantial number of Ki67^+^/γH2AX^+^ hepatocytes. The latter were significantly lower prior to ALPPS, and in the non-regenerating right liver lobe that had been de-portalized ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Thus, replication stress due to increased proliferation also occurs in regenerating human livers.

Next, we aimed to investigate whether replication stress and the associated DNA DSB were determined mainly by hepatocyte proliferation, or also directly affected by TNFR1, caspase-8, or RIPK3. To this end, we analyzed livers of TNFR1/2^−/−^, RIPK3^−/−^, and Casp8^Δhep^ mice 48 hr post-PHX. Whereas similar levels of Ki67^+^/γH2AX^+^ hepatocytes (between 25% and 35%) were detected in livers of wild-type, TNFR1/2^−/−^, and RIPK3^−/−^ mice, unexpectedly \<10% of hepatocytes from livers of Casp8^Δhep^ mice were Ki67^+^/γH2AX^+^ ([Figures 5](#fig5){ref-type="fig"}H and 5I). Notably, at the same time PFGE clearly demonstrated DSB in Casp8^Δhep^ mice ([Figures 5](#fig5){ref-type="fig"}J and 5K), suggesting that caspase-8 plays an important role in sensing or mediating DNA replication-associated damage in hyper-proliferating hepatocytes.

Phosphorylation of Histone H2AX Is Impaired in Caspase-8-Deficient Hepatocytes {#sec3.5}
------------------------------------------------------------------------------

We then sought to determine whether caspase-8 also plays a role in mediating or sensing DNA DSB not related to hyper-proliferation. To this aim, wild-type and Casp8^Δhep^ mice were treated with non-hepatotoxic doses of the genotoxic agent doxorubicin ([@bib48]). Post-application (12 hr), wild-type mice displayed strong γH2AX reactivity in the liver ([Figures 6](#fig6){ref-type="fig"}A, 6B, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B) and other tissues ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Strikingly, although PFGE displayed DNA DSB in livers of Casp8^Δhep^ mice ([Figure 6](#fig6){ref-type="fig"}B), Casp8^Δhep^ hepatocytes were negative for γH2AX, whereas γH2AX^+^ nuclei were still detectable in Kupffer cells and several other caspase-8-proficient cell types ([Figures 6](#fig6){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}C and data not shown). Post-doxorubicin treatment, no apoptotic hepatocytes, no cleavage of caspase-8 above baseline levels ([Figures S7](#mmc1){ref-type="supplementary-material"}D--S7G), or no elevated transaminase levels were detectable ([Figure S7](#mmc1){ref-type="supplementary-material"}H). Thus, H2AX phosphorylation under caspase-8 deficiency is impaired also following doxorubicin-induced DNA damage.Figure 6Caspase-8, RIPK1, FADD, and c-FLIP Are Crucial for Phosphorylation of H2AX in Hepatocytes upon Doxorubicin Treatment(A) IF for γH2AX in untreated wild-type mice and wild-type, Casp8^Δhep^, and QVD-OPH-treated wild-type mice following doxorubicin treatment. Arrow heads illustrate γH2AX^+^ foci in nuclei. Scale bar, 10 μm.(B) PFGE on livers of doxorubicin-treated mice.(C) γH2AX staining of doxorubicin-treated wild-type and caspase-8 D387-mutant mice. Scale bar, 50 μm.(D) γH2AX IF staining 12 hr post-doxorubicin-induced DNA damage in hepatocytes of Casp8^−/−^/RIPK3^−/−^ mice (n = 5), RIPK3^−/−^ mice (n = 4), RIPK1^KD^ mice (n = 9), RIPK1^−/−^RIPK3^−/−^FADD^−/−^ (labeled as R1^−/−^R3^−/−^FADD^−/−^, n = 2), RIPK1^+/−^RIPK3^−/−^FADD^−/−^ (labeled as R1^+/−^R3^−/−^FADD^−/−^, n = 2), c-FLIP^Δhep^ (n = 6), and TNFR1/2^−/−^ mice (n = 6). Arrowheads illustrate γH2AX^+^ foci in nuclei. Scale bar, 10 μm.(E) Quantification of IF stainings (A and D).(F) Immunoprecipitation with anti-caspase-8 antibody (upper panel) and immunoblotting of lysates (lower panel), 0--24 hr after doxorubicin (5 μM) treatment. Red box: RIPK1, FADD, and caspase-8 interaction at 1 hr; blue boxes: low-level activation of apoptosis starting at 4 hr post-treatment. (The signal visible in the t = 0 column, cl.PARP lane, does not originate from cl.PARP, but from a lower unspecific band.) Control cells treated for 1 hr with CD95L/FasL (B, beads; L, lysates).(G) Immunoblotting of lysates, 0--24 hr after doxorubicin (5 μM) treatment looking at levels of total and cl.PARP, blue boxes (F and G): low-level activation of apoptosis starting at 4 hr post-treatment.(H) Levels of LUBAC (HOIP, HOIL-1, and SHARPIN), cIAP1, cIAP2, and XIAP in U2OS cells at 15 min (red box) post-doxorubicin stimulation (5 μM).(I) Subcellular fractionation of U2OS cells.(J) RIPK1 and γH2AX IF staining in U2OS cells after doxorubicin treatment. The arrowhead indicates colocalizing signals. Scale bar, 10 μm.Statistical significance was calculated using ANOVA with Bonferroni correction (E). ^∗∗∗^p \< 0.001. Irrelevant bands were omitted from gels (B). Areas in which lanes were omitted are indicated by white space between lanes. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

The Catalytic Activity of Caspase-8 Is Dispensable for H2AX Phosphorylation {#sec3.6}
---------------------------------------------------------------------------

Pre-treating wild-type mice with the pan-caspase inhibitor QVD-OPH did not abrogate H2AX phosphorylation after doxorubicin application ([Figure 6](#fig6){ref-type="fig"}A). In contrast, QVD-OPH strongly reduced liver damage in mice co-treated with LPS/DGal ([Figures S7](#mmc1){ref-type="supplementary-material"}F--S7H). To exclude incomplete inhibition of caspase-8 activity using QVD-OPH, knockin mice expressing an uncleavable mutant of caspase-8 (D387A) were also treated with doxorubicin ([@bib23]). Similar to wild-type mice, caspase-8 D387-mutant mice revealed γH2AX positivity in hepatocytes upon doxorubicin treatment ([Figure 6](#fig6){ref-type="fig"}C). Consistent with results from conditional caspase-8 knockout mice, we observed significantly reduced γH2AX positivity in Casp8^−/−^/RIPK3^−/−^ livers 12 hr post-treatment ([Figure 6](#fig6){ref-type="fig"}D). In contrast, hepatocytes from RIPK3^−/−^ littermates were positive for γH2AX, consistent with hepatocytes upon PHX of RIPK3^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}H). Collectively, these data show that full-length caspase-8, but not its cleaved form or catalytic activity, is required for H2AX phosphorylation.

H2AX Phosphorylation Is Impaired in Hepatocytes Deficient of c-FLIP, FADD, or RIPK1 Kinase Activity {#sec3.7}
---------------------------------------------------------------------------------------------------

We next investigated whether caspase-8-interacting proteins were involved in H2AX phosphorylation. Doxorubicin-induced H2AX phosphorylation was not affected in TNFR1/2^−/−^ mice, indicating that hepatic H2AX phosphorylation activated by low levels of DNA DSB is not executed by TNFR1/2 signaling complexes. In contrast, c-FLIP-deficient hepatocytes lacked γH2AX positivity post-doxorubicin treatment ([Figures 6](#fig6){ref-type="fig"}D and 6E), pointing to a crucial role of the c-FLIP/Casp8 dimer in DDR. Pharmacological inhibition of RIPK1 by pre-treatment of wild-type mice with necrostatin-1 (Nec1) did not prevent DNA DSB formation, but prevented the appearance of γH2AX^+^ hepatocytes upon doxorubicin treatment ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). This indicated a role of RIPK1 for H2AX phosphorylation *in vivo*. Since Nec1 blocks both RIPK1 assembly and RIPK1 kinase function, we analyzed knockin mice expressing a kinase-inactivated RIPK1 mutant (RIPK1^KD^ mice) and observed significantly impaired H2AX phosphorylation, demonstrating that the kinase activity of RIPK1 is required for H2AX phosphorylation ([Figure 6](#fig6){ref-type="fig"}D). In addition, mice deficient for RIPK1, RIPK3, and FADD (R1^−/−^/R3^−/−^/FADD^−/−^ mice), as well as RIPK1 (haplodeficient), RIPK3, and FADD (R1^+/−^/R3^−/−^/FADD^−/−^ mice), also demonstrated impaired H2AX phosphorylation. Since RIPK3 was not involved in DDR and haploinsufficiency is not reported for RIPK1 ([@bib10]), the lack of γH2AX+ cells in R1^+/−^/R3^−/−^/FADD^−/−^ mice was most likely due to the deletion of FADD. Of note, mice deficient for X-linked inhibitor of apoptosis protein (XIAP^−/−^) clearly showed H2AX phosphorylation upon doxorubicin treatment ([Figure S7](#mmc1){ref-type="supplementary-material"}A). In summary, RIPK1^KD^, Casp8^−/−^/RIPK3^−/−^, R1^−/−^/R3^−/−^/FADD^−/−^, R1^+/−^/R3/FADD^−/−^, and c-FLIP^Δhep^ mice all showed a significantly reduced percentage of γH2AX^+^ foci in hepatocyte nuclei.

Caspase-8 Functions within a Multi-Protein Complex to Orchestrate H2AX Phosphorylation {#sec3.8}
--------------------------------------------------------------------------------------

To test whether a caspase-8-containing protein complex forms in response to DNA DSB, U2OS cells were treated with doxorubicin, followed by time-course immunoprecipitation experiments with an anti-caspase-8 antibody. Starting 30 min post-treatment and peaking at 1 hr, RIPK1 was co-immunoprecipitated with caspase-8, FADD ([Figure 6](#fig6){ref-type="fig"}F, red box), and c-FLIP ([Figure S7](#mmc1){ref-type="supplementary-material"}I, red box). In parallel, γH2AX positivity was detectable starting 1 hr post-doxorubicin treatment. Of note, complex formation 1 hr post-doxorubicin treatment was independent of any apoptotic activity, which was, however, observed between 4 hr (PARP cleavage) and 18--24 hr (caspase-3 cleavage) post-doxorubicin treatment ([Figures 6](#fig6){ref-type="fig"}F and 6G, blue boxes). Importantly, absolute quantification of caspase-8, FADD, c-FLIP, and RIPK1 in caspase-8 immunoprecipitates was performed 1 hr post-doxorubicin treatment by a mass spectrometry-based AQUA method ([@bib36]). This revealed a significant amount of FADD and RIPK1 in complex with caspase-8 in doxorubicin-treated cells ([Figure S7](#mmc1){ref-type="supplementary-material"}J).

Since the linear ubiquitin chain assembly complex (LUBAC) plays a role in preventing cell-death-inducing complex formation in various cell types including hepatocytes ([@bib26], [@bib37]), it was considered a candidate signaling event. Indeed, LUBAC components HOIP, HOIL-1, and SHARPIN, as well as the inhibitor of apoptosis proteins (IAP) cIAP1, cIAP2, and XIAP, known to negatively regulate formation of the ripoptosome ([@bib41]), were transiently reduced 15 to 30 min post-doxorubicin treatment of U2OS cells ([Figure 6](#fig6){ref-type="fig"}H).

Next, we tested whether complex formation in response to DNA damage was paralleled by a change in subcellular localization. Western blot analysis after subcellular fractionation displayed a proportion of RIPK1, caspase-8, and c-FLIP in the nuclear fraction under steady-state conditions, but no enrichment upon doxorubicin-induced DNA damage ([Figure 6](#fig6){ref-type="fig"}I). Localization studies by IF staining and confocal imaging of U2OS cells, with and without doxorubicin, confirmed the induction of nuclear γH2AX positivity, while a minor fraction of RIPK1 was already detectable in the nucleus under steady state ([@bib49]). However, no increased nuclear signal was observed after doxorubicin treatment ([Figure 6](#fig6){ref-type="fig"}J).

JNK Is a Downstream Mediator of Caspase-8- and RIPK1-Dependent H2AX Phosphorylation in Hepatocytes {#sec3.9}
--------------------------------------------------------------------------------------------------

To identify candidate downstream signaling pathways of the DNA damage-sensing platform in hepatocytes, livers of doxorubicin-treated wild-type mice were analyzed for activation of ATM/ATR targets CHK1 and CHK2 ([Figures 7](#fig7){ref-type="fig"}A, [S8](#mmc1){ref-type="supplementary-material"}A, and S8B and data not shown). Remarkably, no pCHK1^+^ or pCHK2^+^ hepatocytes were found 12 hr following doxorubicin-induced DNA damage, suggesting that the ATM and ATR kinase activity is rather low at that time, and pointing to DNA damage-transducing pathways other than ATM and ATR signaling. As control, LPS/DGal-induced cell death was associated with pCHK1+ and pCHK2+ apoptotic hepatocytes ([Figure S8](#mmc1){ref-type="supplementary-material"}B). Furthermore, wild-type mice displayed pcJUN+ hepatocytes upon doxorubicin-induced DSB, indicative of activated c-JUN N-terminal kinase (JNK) signaling ([Figures 7](#fig7){ref-type="fig"}A and [S8](#mmc1){ref-type="supplementary-material"}A). Of note, hepatocytes of Casp8^Δhep^, RIPK^KD^, Nec1-treated, c-FLIP^Δhep^, and Casp8^−/−^/RIPK3^−/−^ mice all lacked substantial pcJUN staining after doxorubicin treatment, in contrast to QVD-OPH-treated wild-type, TNFR1/2^−/−^, RIPK3^−/−^, and XIAP^−/−^mice ([Figures S8](#mmc1){ref-type="supplementary-material"}A and S8B). Co-IF staining for pJNK and γH2AX revealed that wild-type hepatocytes (independent of QVD-OPH pre-treatment) and TNFR1/2^−/−^ hepatocytes had distinct nuclear pJNK signals following doxorubicin treatment, which partially co-localized with γH2AX signals, suggesting JNK as the responsible kinase for H2AX phosphorylation. Casp8^Δhep^, RIPK1^KD^, and c-FLIP^Δhep^ hepatocytes were mostly devoid of pJNK signals ([Figure 7](#fig7){ref-type="fig"}B), suggesting that JNK signaling is downstream of the kinase function of RIPK1, and of caspase-8, FADD, and c-FLIP, and, as such, is involved in H2AX phosphorylation ([@bib32]). Furthermore, mice lacking both JNKs in hepatocytes (JNK1/2^Δhep^ mice) displayed DNA DSB by PFGE, but lacked γH2AX^+^ hepatocytes after doxorubicin treatment ([Figures 7](#fig7){ref-type="fig"}C and 7D). At the same time, PFGE displayed DNA DSB in livers of JNK1/2^Δhep^ mice ([Figure S8](#mmc1){ref-type="supplementary-material"}C).Figure 7JNK Is a Downstream Mediator of Caspase-8-, c-FLIP-, and RIPK1-Dependent Phosphorylation of H2AX *In Vivo* and *In Vitro*(A) Immunohistochemistry for pCHK1, pCHK2, and pcJUN in livers after doxorubicin treatment. Arrowheads indicate pcJUN-positive nuclei. Scale bar, 50 μm.(B) γH2AX and pJNK co-stainings of livers 12 hr post-doxorubicin treatment. Merged: overlay of DAPI, γH2AX, and pJNK staining. Arrowheads indicate IF signals for γH2AX (green), pJNK (red), or overlapping signals of both (yellow). Scale bar, 10 μm.(C and D) IF stainings (C) and quantification for γH2AX in wild-type and JNK1/2-deficient hepatocytes 12 hr post-doxorubicin treatment (D). Arrowheads indicate IF signals for γH2AX. Scale bar, 10 μm.(E) Analysis of DDR signaling by western blotting of lysates from doxorubicin-treated caspase-8 knockdown cells, JNK inhibitor (SP600125) and ATM inhibitor (KU-55933) pre-treated control cells (U2OS). Red boxes: differences in γH2AX and pJNK activation post-doxorubicin treatment between control cells and lentiviral caspase-8 knockdown and JNK inhibitor treated cells. Statistical analysis was corrected for three tests using the Bonferroni method. See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

JNK Is a Downstream Mediator of Caspase-8- and RIPK1-dependent DDR Also in Cell Types Other than Hepatocytes {#sec3.10}
------------------------------------------------------------------------------------------------------------

To determine whether caspase-8 and JNK were involved in H2AX phosphorylation in non-hepatocytic cells, caspase-8 was knocked down in U2OS cells. As expected, shCASP8 lentivirus-transfected U2OS cells were less sensitive to TNF-α-mediated apoptosis compared with shCTRL cells ([Figure S8](#mmc1){ref-type="supplementary-material"}D). As observed *in vivo*, shCTRL cells also displayed a clear increase in γH2AX 30 min post-doxorubicin administration and a strong pJNK signal, but no obvious ATM or ATR activation ([Figure 7](#fig7){ref-type="fig"}E). Strikingly, upon doxorubicin treatment, knock down of caspase-8 substantially decreased γH2AX, pJNK, and pcJUN in shCASP8 cells compared with shCTRL cells ([Figures 7](#fig7){ref-type="fig"}E and [S8](#mmc1){ref-type="supplementary-material"}E). Pre-treatment of shCTRL cells with a JNK inhibitor (JNKi), but not with an ATM inhibitor (ATMi), abolished c-JUN activation and decreased H2AX phosphorylation similar to shCASP8 cells ([Figure 7](#fig7){ref-type="fig"}E, red boxes). Combining ATMi and JNKi reduced γH2AX signals in shCASP8 cells, and led to minimal activation of ATR ([Figure S8](#mmc1){ref-type="supplementary-material"}E). To exclude that data were cell line-specific, HepG2 cells were analyzed, revealing a caspase-8- and JNK-dependent γH2AX increase 30 min post-doxorubicin administration ([Figure S8](#mmc1){ref-type="supplementary-material"}F, red boxes).

Next, we analyzed potential downstream targets of the caspase-8-containing complex regulating H2AX phosphorylation. Of note, IF staining for p53-binding protein 1 (53BP1), an important regulator of the cellular response to DNA DSB ([@bib31]), revealed that, in response to doxorubicin treatment, 53BP1 nuclear positivity was absent in shCASP8 cells, similar to γH2AX 30 min following doxorubicin treatment ([Figure S8](#mmc1){ref-type="supplementary-material"}G). This indicated impaired recruitment of 53BP1 to sites of DNA DSB under caspase-8 deficiency. Aiming to identify further signaling pathways involved in caspase-8-dependent H2AX phosphorylation, we analyzed MAPK and phosphatidylinositol 3-kinase signaling pathways. We found reduced activation of p38 and ERK1/2 under steady-state conditions in shCASP8 cells. At the same time total levels of ERK1/2 and also AKT2 were increased ([Figure S8](#mmc1){ref-type="supplementary-material"}H, red boxes). Doxorubicin treatment induced activation of ERK1/2 and AKT2, whereas p38 activation was impaired in shCASP8 cells. Thus, caspase-8 interferes with or controls MAPK signaling under steady-state and doxorubicin-challenged conditions. Looking for an interaction between JNK and γH2AX in human livers, we found mostly overlapping signals for pJNK and γH2AX in liver tissues of patients with chronic low-level, CLD-related liver regeneration and acute high-level liver regeneration after ALPPS, indicating a role of JNK in mediating DDR ([Figure 8](#fig8){ref-type="fig"}A).Figure 8Evidence for JNK-Dependent DDR in Human Regenerating Livers and Caspase-8 in Human HCC(A) γH2AX and pJNK co-stainings demonstrating JNK-dependent phosphorylation of H2AX in liver tissue of CLD patients or the left lobe of patients after (right) portal vein ligation and liver transection (PVL/LT). Arrowheads indicate IF signals for γH2AX (green), pJNK (red), or overlapping signals of both (yellow). Scale bar, 10 μm.(B) Overall survival of HCC patients depending on HCC caspase-8 expression level (\<mean+1SD; n = 307 patients; \>mean+1SD; n = 51 patients, log rank test, statistical analysis was corrected for three tests using the Bonferroni method. The Cancer Genome Atlas \[TCGA\] cohort).(C) Overall survival of HCC patients depending on HCC caspase-8 methylation status (n = 358 patients, TCGA cohort, log rank test).

Finally, we analyzed publically accessible databases to address whether caspase-8 expression affects HCC biology. Although different datasets yielded variable results, analysis of the largest, most stringent cohort (n = 358 patients) from The Cancer Genome Atlas data portal, validated by the Universal exPression Codes method, revealed that HCC with low caspase-8 expression levels were associated with a better overall survival compared with HCC with high caspase-8 expression ([Figure 8](#fig8){ref-type="fig"}B). Moreover, high caspase-8 expression correlated with high PCNA and Ki67 expression (PCNA versus CASP8: p = 2 × 10^−22^, Ki67 versus CASP8: p = 3 × 10^−25^; data not shown), indicating high proliferative activity. Finally, HCC with methylation of the caspase-8 gene exhibited a better overall survival compared with caspase-8-unmethylated HCC ([Figure 8](#fig8){ref-type="fig"}C). These findings suggest that low caspase-8 expression is associated with a less aggressive behavior of HCC.

Discussion {#sec4}
==========

Hepatocyte apoptosis, a hallmark of CLDs, plays opposing roles in liver homeostasis: on the one hand, it constitutes a hepato-protective mechanism by eliminating damaged hepatocytes. On the other hand, chronically increased hepatocyte apoptosis is harmful.

Here, we show that persistently increased levels of hepatocyte apoptosis tightly correlate with subsequent HCC development: (1) CLD patients who developed HCC had higher preceding transaminase levels compared with case-control matched pairs. (2) Mcl-1^Δhep^ mice and Mcl-1^Δhep^/TNFR1^−/−^ mice that developed liver tumors had higher levels of transaminase activity early in life compared with littermates without tumors. (3) Genetically reducing apoptosis in Mcl-1^Δhep^ mice, by additional deletion of TNFR1 (here) or BAK ([@bib22]), decreased tumorigenesis similar to TAK1^Δhep^ mice with additional caspase-8 (apoptosis) but not RIPK3 (necroptosis) deficiency ([@bib45]). Collectively, these data identify chronically increased hepatocyte apoptosis as a major risk for subsequent HCC development.

By demonstrating (1) increased γH2AX^+^ hepatocytes, indicative of DDR, in both hyper-apoptotic, hyper-regenerating livers of CLD patients and CLD mouse models, and (2) a significant level of AI at CFS in these same livers, we link chronically increased hepatocyte apoptosis with HCC development. Liver regeneration results in DNA replication stress, making hepatocyte proliferation a genotoxic stimulus inducing DNA damage and genetic instability. DNA replication is a major genotoxic stress due to the risk of nucleotide misincorporation, the intrinsic fragility of replicating chromosomes, and the abundance of repetitive and unusual DNA structures in particular at CFS. Genome stability pathways address these challenges and minimize replication-associated risks, but require extra time in cell cycle progression and are often limited in hyper-proliferative states ([@bib17]).

Our findings in human CLD and murine CLD models, underpinned by stochastic considerations ([Figure S4](#mmc1){ref-type="supplementary-material"}), argue that persistently increased hepatocyte apoptosis resulting in regenerative proliferation and high DNA replication rate (independent of etiology) is a decisive determinant of hepatocarcinogenesis. This is in line with a recent report on the carcinogenic effect of replication errors stochastically occurring in highly proliferative stem cells ([@bib43]). This concept also explains most HCC epidemiological data, i.e., that CLD patients are at risk to develop HCC, and that the risk increases with disease activity and duration.

Dissecting the role of caspase-8 for hepatocyte apoptosis, we discovered a non-apoptotic function of caspase-8 in H2AX phosphorylation. Firstly, by performing PHX in C57BL/6 and Casp8^Δhep^ mice, we show that caspase-8 is needed for an efficient DDR to replication stress. Secondly, we found that doxorubicin-induced H2AX phosphorylation in mice was not deficient in livers pretreated with the pan-caspase inhibitor (QVD-OPH), or livers of caspase-8 D387A mutant mice ([@bib23]), but in mice that were full knockout for caspase-8. Thus, DDR was not dependent on caspase-8 catalytic activity, but rather on a non-apoptotic, e.g., a scaffold function of caspase-8. Aiming to identify caspase-8-interacting molecules, we discovered a signaling platform comprising also RIPK1, FADD, and c-FLIP. These molecules are also central in a complex which assembles independently of death receptor activation, referred to as the ripoptosome ([@bib41]). It acts cooperatively in different combinations: (1) to control cell fate upon genotoxic stress in concert with NEMO ([@bib6]), (2) together with RIPK3 to control the non-canonical inflammasome activation ([@bib24]), (3) together with RIPK1 to control TNF-α expression NF-κB independently via JNK ([@bib8]), and together with caspase-3 to suppress necrosis ([@bib7]). Moreover, (4) a different complex, the PIDDosome ([@bib42]), is activated by ATM and executes apoptosis in response to DNA damage ([@bib3]). Finally, (5) it was demonstrated recently that a structural (rather than enzymatic) function of these signaling complex is central for the production of chemotactic cytokines ([@bib18], [@bib21]). Although not providing a direct proof of their regulatory function, the downregulation of LUBAC components and IAPs occurring in temporal association with the formation of the complex discovered here is remarkable. It is reminiscent of the formation of the above-mentioned related complexes. Collectively, findings from all these studies suggest that a defined set of molecules constitutes a dynamic and temporary signaling platform. This platform integrates various inputs (e.g., genotoxic stress, inflammatory signals) resulting in different outputs (e.g., cell death, cytokine production, DDR), thus efficiently coordinating cell fate. We consider the complex found in this study to represent one possibility of these responses, most likely to DNA DSB. Although we found no obvious nuclear localization after induction of DNA damage, our observations do not preclude that under steady state a minor nuclear fraction of the above described components remains functionally activatable to form a complex, as described elsewhere ([@bib49]).

We observed (1) impaired pJNK and pcJUN response to doxorubicin in caspase-8-deficient cells, (2) impaired H2AX phosphorylation after pharmacological inhibition of JNK in various cell lines (U2OS, HepG2) in response to doxorubicin, and (3) impaired H2AX phosphorylation in doxorubicin-treated livers of JNK1/2^Δhep^ mice, all implicating a possible involvement of JNK signaling. However, performing several *in vivo, ex vivo,* and *in vitro* experiments to investigate the downstream signaling modes of this pathway did not give conclusive results. The co-localization of pJNK and γH2AX in human and murine hepatocyte nuclei suggested a link between pJNK and H2AX phosphorylation, in line with previous reports ([@bib32]). Moreover, activation of the ATM/ATR and JNK signaling in human and murine CLDs suggested that all pathways might be present. In contrast, doxorubicin-induced DNA DSB appeared to preferably activate the JNK signaling pathway, whereas the ATM/ATR signaling pathway was activated less in a model- and time-dependent fashion. This inter-experimental variation made it challenging to clearly demonstrate whether or not the ATM/ATR signaling was generally activated by the caspase-8/RIPK1/c-Flip/FADD pathway. Due to the different kinetics in *in vivo* and also in distinct *in vitro* model systems, a uniform pattern of ATM/ATR activation was not identifiable. Interestingly, combined use of ATM and JNK inhibitors led to the strongest and most consistent effects in suppressing H2AX phosphorylation upon doxorubicin *in vitro*. Thus, we conclude that (1) doxorubicin might not necessarily reflect the overall *in vivo* signaling behavior of the complex (e.g., kinetics, signaling candidates), and (2) JNK signaling might be only one of several possible downstream mediators of this complex. Based on our findings, we cannot exclude that phosphatidylinositol 3-kinase-related kinases contribute to the DNA damage signaling pathway discovered in this study. Further studies are needed to identify all important downstream signaling mediators of caspase-8-dependent DDR.

Showing that the caspase-8-containing complex triggers H2AX phosphorylation suggests that it controls DNA integrity and thus potentially prevents malignant transformation. If this holds true, loss of caspase-8 can be expected to be genotoxic and generate an environment of genetic instability. In line with these findings, caspase-8 deficiency has been shown to facilitate cellular transformation independently of its killing function ([@bib25]). Loss of caspase-8 expression by either mutations or epigenetic silencing has been reported in murine and human HCC ([@bib27], [@bib38]). Therefore, it is conceivable that loss of caspase-8 in one and the same cell not only confers apoptosis resistance (a hallmark of cancer), but also promotes replication errors, and thus contributes to cancer development. Based on our observations, caspase-8 deficiency is thus expected to predispose to mutations in proliferating non-neoplastic hepatocytes, whereas at the same time it should confer a fitness disadvantage to neoplastic hepatocytes. In line with the latter, data mining using distinct, already published HCC cohorts revealed that low caspase-8 expression in HCC is associated with a less aggressive behavior, reflected by a less proliferative phenotype and a better overall survival. This is reminiscent to the biology of mismatch repair (MMR) deficiency in the colorectum. MMR deficiency on the one hand predisposes to replication errors and cancer development, and on the other hand it results in hyper-mutated tumors with a better prognosis compared with MMR-proficient carcinomas ([@bib16]).

Given the here described role of caspase-8 in DDR, it is at first glance counter-intuitive that deletion of caspase-8 rescued HCC development in TAK1^Δhep^ mice ([@bib45]). However, DNA damage in a hyper-apoptotic environment such as in CLD patients, Mcl-1^Δhep^, or TAK1^Δhep^ mice, is provoked by constantly enhanced regeneration causing replication stress. Taking into account that caspase-8 deficiency in TAK1^Δhep^ mice abolished apoptosis and nearly normalized proliferative levels ([Figure 4](#fig4){ref-type="fig"}C; [@bib45]), it is obvious that TAK1/Casp8^Δhep^ mice are not tumor prone.

In summary, we identified a role of caspase-8 in sensing DNA damage, and have mechanistically linked increased hepatocyte apoptosis with subsequent HCC development.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-RIP3 (phospho S227) antibodyAbcamCat\# ab209384Anti-c-Jun Rabbit polyclonal AntibodyAbcamCat\# ab31367; RRID: [AB_731606](nif-antibody:AB_731606){#intref1010}Purified Mouse Anti-RIP Antibody (38/RIP) (Immunofluorescent imaging)BD BiosciencesCat\# 610459; RRID: [AB_397832](nif-antibody:AB_397832){#intref2010}Phospho Histone H2A.X (ser139) (20E3) Rabbit mAbCell Signaling TechnologiesCat\# 9718; RRID: [AB_2118009](nif-antibody:AB_2118009){#intref3010}RIP (D94C12) XP Rabbit MabCell Signaling TechnologyCat\# 3493; RRID: [AB_2305314](nif-antibody:AB_2305314){#intref4010}Anti-Caspase-3 antibodyCell Signaling TechnologyCat\# 9662; RRID: [AB_331439](nif-antibody:AB_331439){#intref5010}Phospho-p53 (Ser15) (D4S1H) Rabbit mAbCell Signaling TechnologyCat\# 12571GAPDH (D16H11) XP Rabbit mAbCell Signaling TechnologyCat\# 5174; RRID: [AB_10622025](nif-antibody:AB_10622025){#intref6010}PCNA (PC10) Mouse mAbCell Signaling TechnologyCat\# 2586; RRID: [AB_2160343](nif-antibody:AB_2160343){#intref7010}Phospho-ATM (Ser1981) (D6H9) Rabbit mAbCell Signaling TechnologyCat\# 5883; RRID: [AB_10835213](nif-antibody:AB_10835213){#intref8010}Phospho-Chk1 (Ser345) (133D3) Rabbit mAbCell Signaling TechnologyCat\# 2348; RRID: [AB_331212](nif-antibody:AB_331212){#intref9010}Phospho-SAPK/JNK (Thr183/Tyr185) AntibodyCell Signaling TechnologyCat\# 9251; RRID: [AB_331659](nif-antibody:AB_331659){#intref5115}Phospho-Chk2 (Thr68) AntibodyCell Signaling TechnologyCat\# 2661; RRID: [AB_331479](nif-antibody:AB_331479){#intref0210}Phospho-ATR (Ser428) AntibodyCell Signaling TechnologyCat\# 2853; RRID: [AB_2290281](nif-antibody:AB_2290281){#intref0310}Phospho-BRCA1 (Ser1524) AntibodyCell Signaling TechnologyCat\# 9009; RRID: [AB_491003](nif-antibody:AB_491003){#intref0410}Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAbCell Signaling TechnologyCat\# 9664; RRID: [AB_2070042](nif-antibody:AB_2070042){#intref0415}Cleaved Caspase-8 (Asp387) (D5B2) XP Rabbit mAbCell Signaling TechnologyCat\# 8592RIP (D94C12) XP Rabbit mAbCell Signaling TechnologyCat\# 3493; RRID: [AB_2305314](nif-antibody:AB_2305314){#intref0510}Cleaved Caspase-1 (Asp296) AntibodyCell Signaling TechnologyCat\# 67314Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAbCell Signaling TechnologyCat\# 4511; RRID: [AB_2139682](nif-antibody:AB_2139682){#intref0610}p38 MAPK (D13E1) XP Rabbit mAbCell Signaling TechnologyCat\# 8690; RRID: [AB_10999090](nif-antibody:AB_10999090){#intref0710}c-IAP1 Rabbit polyclonal AntibodyCell Signaling TechnologyCat\# 4952; RRID: [AB_2063660](nif-antibody:AB_2063660){#intref0810}c-IAP2 (58C7) Rabbit mAbCell Signaling TechnologyCat\# 3130; RRID: [AB_10693298](nif-antibody:AB_10693298){#intref0910}XIAP Rabbit polyclonal AntibodyCell Signaling TechnologyCat\# 2042; RRID: [AB_2214870](nif-antibody:AB_2214870){#intref0010a}PARP Rabbit polyclonal AntibodyCell Signaling TechnologyCat\# 9542; RRID: [AB_2160739](nif-antibody:AB_2160739){#intref0010b}Caspase-8 Rabbit polyclonal AntibodyCell Signaling TechnologyCat\# 4927; RRID: [AB_2068301](nif-antibody:AB_2068301){#intref0010c}Alexa Fluor 488 Goat anti-Rat IgG (Immunofluorescent imaging)Life TechnologiesCat\# A11006; RRID: [AB_141373](nif-antibody:AB_141373){#intref0010d}Alexa Fluor 546 Goat anti-Rabbit (Immunofluorescent imaging)Life TechnologiesCat\# A11010; RRID: [AB_143156](nif-antibody:AB_143156){#intref0010e}Goat anti-Mouse IgG Alexa Fluor 488 (Immunofluorescent imaging)Life TechnologiesCat\# A11029; RRID: [AB_138404](nif-antibody:AB_138404){#intref0010f}NA19L Anti-replication Protein A (Ab-3) Mouse mAb (RPA34-20)Merck (Calbiochem)Cat\# NA19L; RRID: [AB_565123](nif-antibody:AB_565123){#intref0010g}Ki-67 (SP6) Rabbit mAbNeomarkers / Lab vision CorporationCat\# RM9106; RRID: [AB_2335745](nif-antibody:AB_2335745){#intref0010h}Cleaved caspase-8 Rabbit polyclonal AntibodyNovus BiologicalsCat\# NB100-56116; RRID: [AB_837874](nif-antibody:AB_837874){#intref0010k}Chk1 \[p Ser317\] Rabbit polyclonal AntibodyNovus BiologicalsCat\# NB100-92499; RRID: [AB_1216466](nif-antibody:AB_1216466){#intref0010l}p-Chk2 \[p Thr68\] Rabbit polyclonal AntibodyNovus BiologicalsCat\# NB100-92502; RRID: [AB_1216474](nif-antibody:AB_1216474){#intref0010m}gamma H2AX \[p Ser139\] Rabbit polyclonal Antibody (Immunofluorescent imaging)Novus BiologicalsCat\# NB100-2280; RRID: [AB_10000580](nif-antibody:AB_10000580){#intref0010n}gamma H2AX (p Ser139) Rabbit polyclonal AntibodyNovus BiologicalsCat\# NB100-384; RRID: [AB_350295](nif-antibody:AB_350295){#intref0010o}SHARPIN Rabbit polyclonal AntibodyProteintechCat\# 14626-1-AP; RRID: [AB_2187734](nif-antibody:AB_2187734){#intref0010p}Caspase-8 p18 Antibody (H-134)Santa Cruz BiotechnologyCat\# sc-7890; RRID: [AB_2068330](nif-antibody:AB_2068330){#intref0010q}p-c-Jun Goat polyclonal Antibody (Ser 63/73)Santa Cruz BiotechnologyCat\# sc-16312; RRID: [AB_2129883](nif-antibody:AB_2129883){#intref0010r}p-Akt1/2/3 Rabbit polyclonal Antibody (Ser 473)Santa Cruz BiotechnologyCat\# sc-7985-R; RRID: [AB_667741](nif-antibody:AB_667741){#intref0010s}Akt1/2 Goat polyclonal Antibody (N-19)Santa Cruz BiotechnologyCat\# sc-1619; RRID: [AB_671713](nif-antibody:AB_671713){#intref0010t}53BP1 Rabbit polyclonal Antibody (H-300) (Immunofluorescent imaging)Santa Cruz BiotechnologyCat\# sc-22760; RRID: [AB_2256326](nif-antibody:AB_2256326){#intref0010w}Human HOIP/RNF31 AntibodyR&D SystemsCat\# AF8039Anti-BrdU antibody, Mouse Monoclonal (clone BU-33)Sigma-AldrichCat\# B8434; RRID: [AB_476811](nif-antibody:AB_476811){#intref0010x}Anti-actin N terminal antibodySigma AldrichCat\# A2103; RRID: [AB_476694](nif-antibody:AB_476694){#intref0010y}Anti-ATM Mouse mAbSigma-AldrichCat\# A1106; RRID: [AB_796190](nif-antibody:AB_796190){#intref0010z}C15 (anti-caspase 8)Prof. Peter H Krammer (DKFZ, Heidelberg)N/A1C4 (anti-FADD)Prof. Peter H Krammer (DKFZ, Heidelberg)N/AHuman HOIL-1 AntibodyPrepared in house[@bib19]**Bacterial and Virus Strains**lentiviral particles for caspase-8Santa CruzCat\# sc-29930-Vlentiviral particles for controlSanta CruzCat\# sc-108080**Biological Samples**Liver tissue from mice after Vitamin E dietThis paperN/ALiver tissue from mice after BHA dietThis paperN/ALiver tissue from mice after two-third partial hepatectomy[@bib39]N/ALiver Tissue from mice after LPS/D-Gal treatmentThis paperN/ALiver tissue from mice after Doxorubicin treatmentThis paperN/ALiver tissue from various mutant mice and intercrossings[@bib44], [@bib45], [@bib30], [@bib23], [@bib9], [@bib10], this paperN/A**Chemicals, Peptides, and Recombinant Proteins**DoxorubicinSigma-AldrichCat\# D1515DMSOSigma-AldrichCat\# 276855Q-VD-OPHSigma-AldrichCat\# SML0063Necrostatin1Sigma-AldrichCat\# N9037D-(+)-GalactosamineSigma-AldrichCat\# G0500LipopolysaccharideSigma-AldrichCat\# F3665BuprenorphineMSD Sharp & Dohme GmbHNDC 12496-0757-5DAPILife\
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Fwd TCAAAGATGGCGTAACAAACTGG\
Rev CCCGTTTCGTCCTTACAAGAACThis paperN/AMurine Tnf-α\
Fwd CATCTTCTCAAAATTCGAGTGACAA\
Rev TGG GAGTAGACAAGGTACAACCCThis paperN/AMurine Trail\
Fwd CGGGCAGATCACTACACCC\
Rev TGTTACTGGAACAAAGACAGCCThis paperN/AMurine TrailR\
Fwd AGTAGTGCTGCTGATTGGAG\
Rev CCTGTTTTCTGAGTCTTGCCThis paperN/AMurine Fas\
Fwd TGCACCCTGACCCAGAATAC\
Rev GCCAGGAGAATCGCAGTAGAAThis paperN/AMurine FasL\
Fwd GCAAATAGCCAACCCCAGTACAC\
Rev GCCACCTTTCTTATACTTCACTCCAGThis paperN/AMurine Tnfr1\
Fwd CACCGTGACAATCCCCTGTAA\
Rev TTTGCAAGCGGAGGAGGTAGThis paperN/AMurine Tnfr2\
Fwd ACAAAGTACCAAGGGTGGCA\
Rev GGGCTTCTTTTTCCTCTGCACThis paperN/AMurine IL-6\
Fwd TAGTCCTTCCTACCCCAATTTCC\
Rev TTGGTCCTTAGCCACTCCTTCThis paperN/AMurine IL-1α\
Fwd CGA AGC TCT CCG TAC ATT CC\
Rev TAA GGA CGG GAG GGA GAA AGThis paperN/AMurine IL-1β\
Fwd TAA GGA CGG GAG GGA GAA AG\
Rev GAT CCA CAC TCT CCA GCT GCAThis paperN/AMurine IL-18\
Fwd GAC TCT TGC GTC AAC TTC AAG G\
Rev CAG GCT GTC TTT TGT CAA CGAThis paperN/AMurine Ifn-γ\
Fwd GCA TCC AAA AGA GTG TGG AG\
Rev GCA GGC AGG ACA ACC ATT ACThis paperN/AMurine Gadd45a\
Fwd AGC ACG CAA AAG GTC ACA TTG\
Rev GGG AAA GCA CTG CAC GAA CTThis paperN/AMurine Actin\
Fwd GTGGGCCGCCCTAGGCACCA\
Rev CTCTTTGATGTCACGCACGATTTCThis paperN/AMurine GAPDH\
Fwd CCACCCCAGCAAGGAGACT\
Rev GAAATTGTGAGGGAGATGCTThis paperN/AMurine Rad51\
Fwd CGGGAGTTGGTGGGTTATCC\
Rev CCGGCACATCTTGGTTTATTTGTThis paperN/AMurine Exo1\
Fwd ATGGGGATTCAAGGGTTACTTCA\
Rev AGCCAACAGTAGGTATCCACAGThis paperN/AMurine Ddit3\
Fwd CTCGCTCTCCAGATTCCAGTC\
Rev CTTCATGCGTTGCTTCCCAThis paperN/AMurine PolE2\
Fwd TCCTCGAACATGATCGAACGA\
Rev ACGTGGAATATCAAAAGCTCCAAThis paperN/AMurine PolQ\
Fwd GCTTGGTCACGTCTTGGAAG\
Rev GGGCAAAATAAACAACGCTTTCTThis paperN/AMurine Ddb1\
Fwd ATGTCGTACAACTACGTCGTAAC\
Rev CTGAAGTAAAGTGTCCGGTCACThis paperN/AMurine Chek2\
Fwd CTGAAGTAAAGTGTCCGGTCAC\
Rev CACCACCCGGTCAAATAGTTCThis paperN/AMurine Lig1\
Fwd CCAGCTCATAGTCCCCTCTGA\
Rev GTCTTGGCACCTCTAGCAGGThis paperN/AHuman Actin\
Fwd ATGGCCCTGTGCCTTAGTAG\
Rev GGTCTCAAACATGATCTGGGThis paperN/AHuman GAPDH\
Fwd CCT GGT CAC CAG GGC TGC\
Rev CCG TTC TCA GCC TTG ACG GThis paperN/AHuman Rad51\
Fwd TTTGGTGAGTTTCCCGCTGTC\
Rev AACTTCTTTGCTAAGCTCGGAGThis paperN/AHuman Exo1\
Fwd CCTCGTGGCTCCCTATGAAG\
Rev AGGAGATCCGAGTCCTCTGTAAThis paperN/AHuman Ddit3\
Fwd GGAAACAGAGTGGTCATTCCC\
Rev CTGCTTGAGCCGTTCATTCTCThis paperN/AHuman PolE2\
Fwd TGAGAAGCAACCCTTGTCATC\
Rev TCATCAACAGACTGACTGCATTCThis paperN/AHuman PolQ\
Fwd ACCTCTCCATCAAGGCATTTCT\
Rev GCAAAAGTTCCAGCAGATACCThis paperN/AHuman Ddb1\
Fwd ACCGGACACTTTACTTCGGC\
Rev TCGGCGGTGACCACATAGAThis paperN/AHuman Chek2\
Fwd TGAGAACCTTATGTGGAACCCC\
Rev ACAGCACGGTTATACCCAGCThis paperN/AHuman Lig1\
Fwd ACAGTTCCCCATCAGGGATTC\
Rev CTCTGTGAGGCTTTCTTTCGGThis paperN/AHuman Gpnmb\
Fwd AAGTGAAAGATGTGTACGTGGTAACAG\
Rev TCGGATGAATTTCGATCGTTCTThis paperN/AHuman Tinag\
Fwd CGAAAGCTTCAGACACATGC\
Rev TTTCTTTCTGCCCTTGTGCTThis paperN/AHuman Plk1\
Fwd GCTTAATGACGAGTTCTTTACTTC\
Rev TCGAAAACCTTGGTGGAATGThis paperN/AHuman Bcl2a1b\
Fwd ACGACAGCAAATTGCCCCGGAT\
Rev AAGCCATTTTCCCAGCCTCCGTThis paperN/AHuman Tpx2\
Fwd CGAAAGCATCCTTCATCTCC\
Rev TCCTTGGGACAGGTTGAAAGThis paperN/AHuman CD44\
Fwd CCGCTATGTCCAGAAAGGA\
Rev CTGTCTGTGCTGTCGGTGATThis paperN/AHuman Glypican3\
Fwd CCTTTGAAATTGTTGTTCGCCA\
Rev CCTGGGTTCATTAGCTGGGTAThis paperN/AHuman Epcam\
Fwd AATCGTCAATGCCAGTGTAC\
Rev TCTCATCGCAGTCAGGATCATAAThis paperN/AHuman Afp\
Fwd AACTATTGGCCTGTGGCGAG\
Rev TCATCCACCACCAAGCTGThis paperN/AD3S1263-Fwd (FAM labeled)\
CTG TTG ACC CAT TGA TAC CCThermo FisherN/A*D3S1263*-Rev (HEX labeled)\
TAA AAT CAC AGC AGG GGT TCThermo FisherN/A*D3S1289*-Fwd (HEX labeled)\
AAA GCA ACT TGT AAG AGA GCAThermo FisherN/AD3S1289-Rev (FAM labeled)\
CTC CTA GAT ATA ATC ACT GGC AThermo FisherN/A**Software and Algorithms**Copy Caller SoftwareLife Technologies<https://www.thermofisher.com>FlowJo sofwareTreeStar<https://www.flowjo.com>Summit software v4.3Beckman Coulter<https://www.beckman.com>GeneMapper softwareApplied Biosystems<https://www.thermofisher.com>NDP Viewer v1.2.36NDP View<https://www.hamamatsu.com>Tissue IA image 2.0Leica Biosystems[www.leicabiosystems.com](http://www.leicabiosystems.com){#intref0055}GeneSpring GXAgilent<http://www.genomics.agilent.com>GESA Molecular Signatures Database<http://www.broadinstitute.org>Xcalibur software 2.2Thermo Fisher Scientific<https://www.thermofisher.com>R statistical programming language 3.2.2R Foundation for Statistical Computing<https://www.R-project.org/>cgdsr R package (R-Based API for Accessing the MSKCC Cancer Genomics Data Server (CGDS))CRAN repository<https://CRAN.R-project.org/package=cgdsr>SCAN.UPC R packageBioconductor project<https://bioconductor.org/packages/SCAN.UPC>**Other**ABI 3130XL Genetic AnalyzerApplied Biosystems<https://www.thermofisher.com>Stella 3200 imaging systemRaytest<https://www.raytest.com/>Nano Zoomer C9600 Virtual Slide Light microscope scannerHamamatsu<https://www.hamamatsu.com>

Contact for Reagent and Resource Sharing {#sec5.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Achim Weber (<achim.weber@usz.ch>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Human Material {#sec5.3.1}

Snap-frozen and formalin-fixed, paraffin-embedded (FFPE) human liver tissue samples were retrieved from the archives and the biobank of the Department of Pathology and Molecular Pathology, University Hospital Zurich, for morphological and molecular analyses. The study was and approved by the local ethics committee ("Kantonale Ethikkommission Zürich", application numbers StV26/2005 and KEK-ZH-Nr. 2013-0382).

### Mice {#sec5.3.2}

All animal experiments conformed to the relvant regulatory standards and were approved by the Swiss Veterinary Office (134/2014, 217/2012, 63/2011 Zurich). Animals were maintained under pathogen-free conditions and experiments were performed in accordance to the guidelines of the Swiss Animal Protection Law, Veterinary Office, Canton Zurich. Generation of mice with hepatocyte-specific Mcl-1 knock-out (homozygous: AlbCre^tg/+^/Mcl-1^flox/flox^ (Mcl-1^Δhep^), heterozygous AlbCre^tg/+^/Mcl-1^flox/wt^) ([@bib44]), with hepatocyte-specific c-Flip knockout and Tak1^Δhep^, Casp8^Δhep^, Tak1/Casp8^Δhep^ and Tak1^Δhep^/RIPK3^-/-^ mice ([@bib45]), Xiap^−/−^ mice ([@bib30]), and caspase 8 D387-mutant mice ([@bib23]), was as described (see also [Table S1](#mmc1){ref-type="supplementary-material"}). TNFR1^-/-^ and TNFR1/2^-/-^ mice were purchased from Jackson Laboratories and TNFR1^-/-^ mice intercrossed to Mcl-1^Δhep^ mice and bred in JNK1/2^Δhep^ mice were generated by crossing with JNK1/2^*loxP*/*loxP*^ mice ([@bib9]). Alb-Cre mice were bred in house ([@bib20]). Ripk1^-/-^/Ripk3^−/−^/Casp8^−/−^, Ripk3^−/−^/Casp8^−/−^ and Ripk3^−/−^ mice were previously described ([@bib10]).

### Cell Lines and Drug Treatments {#sec5.3.3}

U2OS and HepG2 were grown in DMEM containing 10% FBS and 1% penicillin/streptomycin. Cells were transfected with lentiviral particles for caspase-8 (Santa Cruz, sc-29930-V) or control particles (Santa Cruz, sc-108080) according to the manufacturer\'s protocol and cells stably expressing the shRNA were isolated by puromycin selection (Santa Cruz). Cells were treated as indicated with Doxorubicin (Sigma) and for inhibition experiments, cells were pretreated for 4h with 10μM of the ATM inhibitor KU-55933 (Selleckchem) or pretreated with the JNK inhibitor (SP600125, Selleckchem) at 25μM and Doxorubicin added and cells incubated for indicated time. Cells 2h post irradiation with 10Gy were used as controls.

Method Details {#sec5.4}
--------------

### Human Cohort Studies {#sec5.4.1}

For evaluation of liver function tests as potential predictors of HCC development, HCV patients with confirmed diagnosis of HCC and HCV patients without HCC were selected from the patient database as matched pairs according to MELD score for the given time point before the HCC diagnosis. The MELD score was chosen as the current international standard for assessment of severity of liver disease e.g. in liver transplant organ allocation and is based on laboratory values bilirubin, creatinine and INR. HCV patients who underwent liver transplantation (Swiss Hepato-Pancreato-Biliary Center, University-Hospital Zurich) due to liver tumors were chosen for the transplantation study, and compared to HCV patients which underwent liver transplantation, but did not develop liver tumors.

### Mouse Strains and Intercrossings {#sec5.4.2}

Live damage of mice at the indicated age and tumor incidence analyzed at 12 months of age for Mcl-1^Δhep^ and Mcl-1^Δhep^/TNFR1^-/-^ mice and 33-35 weeks of age for TAK1^Δhep^ mice and intercrossings. For overview, please also see [Table S1](#mmc1){ref-type="supplementary-material"}.

### Measurement of Serum Parameters {#sec5.4.3}

The analysis of aminotransferases (ALT/AST) and bilirubin was performed with mouse serum on a Roche Modular System (Roche Diagnostics) with a commercially available automated colorimetric system at the Institute of Clinical Chemistry, University Hospital Zurich, using a Hitachi P-Modul (Roche).

### RNA Isolation from Liver Tissue {#sec5.4.4}

Total RNA from snap-frozen human liver biopsies or mouse livers was isolated using RNeasy Mini Kit (Qiagen) according to the manufacturer\'s protocol. The quantity and quality of the RNA was determined spectroscopically using a Nanodrop (Thermo Scientific).

### Real-time PCR {#sec5.4.5}

Total RNA (1 μg) was reversely transcribed into cDNA using Quantitect Reverse Transcription Kit (Qiagen) according to the manufacturer's protocol. For *mRNA* expression analysis real-time PCR was performed (reactions in duplicates) using Fast Start SYBR Green Master Rox (Roche). Real-time PCR was performed on an ABI PRISM 7900 HT and VIIA7 Fast Real-Time PCR System (AB). Data were generated and analyzed using SDS 2.4 and RQ manager 1.2 software. *mRNA* expression levels were normalized to the housekeeping genes *Hprt* for human samples, *and Gapdh f*or murine samples*.*

### DNA Extraction {#sec5.4.6}

Genomic DNA was isolated from 2 μm sections of murine or human FFPE slides by scrapings and tissue digested with Proteinase K overnight. After Proteinase K inactivation for 10 min at 95°C DNA concentration was determined spectroscopically using a Nanodrop (Thermo Scientific) and appropriate genomic DNA was directly used for PCR reactions in duplicates.

### Taqman Copy Number Analysis {#sec5.4.7}

Taqman copy number analysis was carried out as multiplex PCR in duplicates with 20 ng DNA per reaction and *Ttert* as internal reference according to the manufacturer's protocol. *Wwox*, *Spata22*, *Fhit* were selected as described markers from common fragile sites in humans and *Fgfr1* and *Fgr* were selected as genes of interest in previously published areas of genetic instability in Tak1^Δhep-/-^ mice ([@bib5]). Data analysis was performed using Copy Caller Software (Life Technologies).

### Flow Cytometry for DNA Damage {#sec5.4.8}

Primary murine hepatocytes were isolated by the two-step collagenase perfusion method, purified by Percoll gradient and finally collected in RPMI 1640 medium for flow cytometry procedures. Next, hepatcytes were fixed and permeabilized, followed by incubation with antibodies against γH2AX (\#9718; Cell Signaling Technology) and RPA (NA19L, Calbiochem) and suitable secondary antibodies. DNA was stained with 1 μg/ml DAPI. Samples were measured on a Cyan ADP flow cytometer (Beckman Coulter) and analyzed with Summit software v4.3 (Beckman Coulter).

### Partial Hepatectomy (PHX) {#sec5.4.9}

Eight- to twelve-week-old male mice with indicated genotype received food and water ad libitum before surgery. Mice were anaesthetized by inhalation of isoflurane (2%). PHX was performed between 8 and 12 a.m..Three liver lobes, including the previously emptied gall bladder, were removed. After surgery, mice were injected with buprenorphine for analgesia (Temgesic; Essex Chemie AG, Luzern, Switzerland; 0.1 mg/kg of body weight). Mice were euthanized by CO2 inhalation, and the remaining liver was harvested at different time points after PHX for further analysis ([@bib39]).

### BrdU Assay {#sec5.4.10}

Proliferating cells were identified by 5-bromo-2′-deoxyuridine (BrdU) labelling. For this purpose, BrdU (Sigma, Buchs, Switzerland; 250 μg/g body weight) was injected i.p. prior to PHX. Two hours later, PHX was performed and mice were sacrificed at indicated time points. Detection of BrdU-positive cells was performed by immunofluorescence stainings using a peroxidase-coupled antibody against BrdU (1:30; Roche, Switzerland) ([@bib39]).

### Immunoprecipitation {#sec5.4.11}

Cells were lysed in 1 ml lysis buffer (20 mM Tris HCl, pH 7.4, 137 mM NaCl, 2 mM EDTA, 10% glycerine, 1% Triton X-100, 1 mM PMSF, Protease Inhibitor mix (Roche)) for 30 min on ice. Afterwards, the samples were centrifuged at 14.000 rpm for 15 min at 4°C. 50 μl supernatant was used as lysate control. The remaining supernatant was immunoprecipitated by mixing with 30 μl protein A-Sepharose and 2 μg of C15 antibodies. Immunoprecipitations were performed for at least 2h at 4°C and washed four times with PBS. Samples were subjected to SDS PAGE (Biorad) and transferred to Hybond nitrocellulose membrane using the Western Blot system (Biorad). Membranes were blocked with 5% nonfat dry milk in PBS-T (PBS + 0.05% Tween 20) for 1 h, washed with PBS-T 3x for 10 min and incubated with the primary antibody in PBS/Tween for 1h at room temperature. C15 (anti-caspase 8) and 1C4 (anti-FADD) antibodies were a kind gift of Prof. Peter H. Krammer (DKFZ, Heidelberg). The following antibodies were used: anti-RIPK1 (D94C12), Cell Signaling, anti-Casp3 (9662), Cell Signaling and anti-Actin (A2103), Sigma.

### Fragment Length Analysis for Allelic Imbalance {#sec5.4.12}

For analysis of AI the markers *D3S1263* and *D3S1289* at known common fragile sites ([@bib15]) were selected. Four distinct regions (non-inflamed) of interest per liver-needle biopsy were identified by pathologists and gDNA isolated from 2 μm unstained consecutive FFPE sections. PCR products were separated by capillary electrophoresis using the ABI 3130XL Genetic Analyzer (Applied Biosystems) and results were analyzed with the help of GeneMapper software (Applied Biosystems). AI was identified by calculating the fluorescence ratios of heterozygous (informative) markers for each biopsy. The following primers were used: *D3S1263-Fwd* CTG TTG ACC CAT TGA TAC CC (FAM labeled), *D3S1263*-Rev TAA AAT CAC AGC AGG GGT TC, *D3S1289*-Fwd AAA GCA ACT TGT AAG AGA GCA (HEX labeled), D3S1289-Rev CTC CTA GAT ATA ATC ACT GGC A.

### Pulse Field Gel Electrophoresis (PFGE) {#sec5.4.13}

PFGE was performed as published previously ([@bib29]). Briefly, snap-frozen liver tissue was directly put into 4% formaldehyde without thawing and incubated for 10 min at 37°C. Tissue was mechanically dissociated (gentleMACS Dissociator, Miltenyi Biotec), filtered through a 70 μm cell strainer (Falcon) and 2.5x10^5^ cell were embedded in a 0.8% agarose plus, digested in lysis buffer (100 mM EDTA, 1% (wt/vol) sodium lauryl sarcosyne, 0.2% (wt/vol) sodium deoxycholate, and 1 mg/ml proteinase K) at 37°C for 48 h, and washed in 10 mM Tris-HCl, pH 8.0, and 100 mM EDTA. Electrophoresis was performed at 14°C in 0.9% (wt/vol) Pulsed Field Certified Agarose (Bio-Rad Laboratories) containing Tris-borate/EDTA buffer in a CHEF DR III apparatus (9 h, 120°, 5.5 V/cm, 30-18 s switch time; 6 h, 117°, 4.5 V/cm, 18-9 s switch time; 6 h, 112°, 4 V/cm, 9-5 s switch time; Bio-Rad Laboratories). The gel was stained with ethidium bromide and imaged on an Alpha Innotech Imager.

### Immunoblot Analysis {#sec5.4.14}

Snap-frozen liver tissue was dissociated (gentle MACS Dissociator, Miltenyi Biotec) and homogenates (10%) were prepared in RIPA buffer (50 mM Tris; 1% NP40; 0.25% Deoxycholic acid sodium salt; 150 mM NaCl; 1 mM EGTA) containing Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). Quantification with a BCA protein assay kit (Thermo Scientific) according to the manufacturer's manual was followed by denaturation of 80 μg protein in Laemmli buffer containing 5% β-mercaptoethanol and separated by gel electrophoresis (Mini Protean Gels, Bio Rad) and blotted by semi-dry blotting (Trans-Blot Turbo Transfer, Bio Rad) onto nitrocellulose membranes (Bio Rad) and stained with Ponceau Red. Membranes were blocked in 5% milk/PBS-T for at least 1 hr at RT. Primary antibodies against γH2AX, p-p53, GAPDH, PCNA, pATM, pCHK1, pJNK1/2, pCHK2, pATR, pBRCA1, cleaved-Casp1, cleaved-Casp3, cleaved-Casp8, RIPK1, RIPK3, total-JNK1/2, p-p38, p38, cIAP1, cIAP2, XIAP (all Cell Signaling Technology), total-Casp8, p-cJUN, pAKT1/2/3, total AKT (SantaCruz), total-ATM (Sigma), total-cJUN (BD Bioscience), HOIP (R&D), SHARPIN (Proteintech), HOIL-1 (Walczak lab) and Casp8 C15 (provided by Dr. P. Krammer, Heidelberg), were incubated at 4°C overnight under shaking conditions. Incubation with the secondary antibody (HRP-anti rabbit IgG, 1:5000; Promega) was performed under shaking conditions for 1 hr. Detection was achieved with Clarity Western ECL Substrate (Bio Rad) using Stella 3200 imaging system Raytest.

### Histology and Immuno Stainings {#sec5.4.15}

Sections (2 μm) of livers (fixed in 4% paraformaldehyde and paraffin-embedded) were stained with Hematoxylin/Eosin or various antibodies. Incubation in Ventana buffer and staining was performed on a NEXES immunohistochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX (Leica). Immunostainings were performed as described before ([@bib47]) with antibodies against the following proteins: Ki67, 1:200 dilution (SP6, NeoMarkers / Lab Vision Corporation); γH2AX, 1:300 dilution (Novus Biologicals); p-cJUN, 1:100 (Abcam); cleaved-Caspase8, 1:500; p-CHK1, 1:50 and p-CHK2, 1:500 (Novus Biologicals). For virtual microscopy and archiving, histological and immunohistochemical images were digitalized using a Nano Zoomer C9600 Virtual Slide Light microscope scanner by Hamamatsu using NDP, View Software, version 1.2.36. Alternatively, for quantification of stainings, slides were scanned using a SCN 400 slide scanner (Leica) and analyzed using Tissue IA image analysis software (Slidepath, Leica).

### RNA Microarray {#sec5.4.16}

An Agilent one-color microarray-based gene expression analysis (mouse DNA Microarray 4x44K) was performed according to the manufacturer's protocol. Two- and twelve-months-old mice were analyzed. For 12 months, HCC and corresponding non-tumor tissue (n=3) from the same animal (n=5) as well as livers from Cre-negative littermates as controls (n=3) were analyzed. For 2 months, Mcl-1^Δhep^ (AlbCre^tg/+^Mcl-1^flox/flox^), hemizygous Mcl-1^Δhep^ (AlbCre^tg/+^/Mcl-1^flox/wt^) and Cre-negative controls were analyzed. Gene expression was quantified using Agilent Feature Extraction Software Version 9.5.3.1. Gene Ontology microarray data analysis: Lists of significantly differentially expressed genes were investigated in respect to enrichment of Gene Ontology categories using the Gene Ontology Browser as implemented in GeneSpring 7.3. Fisher's exact test was used to show whether more genes belonging to a Gene Ontology category are found in the list under investigation than in a randomized gene list of the same size.

### Gene Set Enrichment Analysis (GSEA) {#sec5.4.17}

Gene sets from the biological process gene ontology for GSEA analysis <http://www.broadinstitute.org> were downloaded from the Molecular Signatures Database or integrated manually into the GSEA for human HCV-induced hepatitis gene expression sets ([@bib34]) or alcohol-induced hepatitis ([@bib1]). GSEA tests whether genes sets were overrepresented in microarray expression data were performed with standard settings.

### Immunofluorescence Stainings and Confocal Microscopy {#sec5.4.18}

U2OS cells were seeded on cover slips and grown to 50-80% confluence for 24 h. Cells were incubated with medium or 1 μM doxorubicin for 30 min and fixed with 4% fomaldehyde for 1 h. Cells were washed with PBS and Tris buffer (100 mM Tris, pH=7.4, 50 mM NaCl), permeabilized with 0.5% Triton X-100 in PBS for 10 min, incubated in blocking solution (PBS, pH=7.4, 1% BSA, 2% FCS) for 20 min, incubated with primary antibody in blocking solution for 12 h at 4°C, washed twice with PBS, incubated with secondary antibody in blocking solution for 3 h, washed with PBS, incubated with 1 μg/ml DAPI (life technologies) for 5-15 min, washed 4 times with PBS and mounted using Vectashield (Vector Laboratories). Primary antibodies and concentrations used for immunofluorescence were γH2AX (Abcam, ab26350, 1:200), γH2AX (Novus Biologicals, NB100-2280, 1:200), RIP1 (BD Biosciences, 610459, 1:50), Caspase 8-C15 and 53BP1 (Santa-Cruz, sc-22760, 1:50). Secondary, Alexa-488 or Alexa-546 labelled antibodies were all from life technologies and used at a 1:500 dilution. Imaging was performed on a Leica SP8 confocal microscope equipped with 405, 488, 552, and 638 nm diode lasers and a 63x oil objective (HC PL APO CS2 / 1.40 oil) using LAS software (Leica Microsystems, Wetzlar Germany) and processed using ImageJ.

### Subcellular Fractionation {#sec5.4.19}

Cells grown on dishes were washed twice with ice-cold PBS and carefully scraped in PBS, centrifuged at 1000 x g for 2 min at 4°C and resuspended in 300 μl buffer A (20 mM Tris/HCl pH 7.9, 10 mM NaCl, 1.5 mM MgCl2, 10 % Glycerol, 0.5 mM DTT, 0.5 mM AEBSF, 1 mM Na3VO4, 1 mM Na2MoO4, 10 mM NaF, 10 mM K2HPO4, 20 mM glycerol-2-phosphate, phosphatase inhibitor tablet (Roche)). After incubation on ice for 10 min, swelling of cells was monitored by microscopy using 0.4% trypan blue staining. For disruption of the cytoplasm membrane cells were treated with 0.125% NP-40 and incubated on ice for 5 min. After centrifugation at 2000 x g for 10 min at 4°C the supernatant was kept as cytosolic fraction (additional centrifugation at 13000 x g for 10 min at 4°C freed the lysate from cell debris). Nuclear fractions were resuspended in 100 μl buffer C (20 mM Tris/HCl pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 10% gycerol, 0.5 mM DTT, 0.2 mM EDTA, 0.5 mM AEBSF, 1 mM Na3VO4, 1 mM Na2MoO4, 10 mM NaF, 10 mM K2HPO4, 20 mM glycerol-2-phosphate, phosphatase inhibitor tablet (Roche)). After incubation for 15 min on ice with occasional vortexing N1 fractions were collected by centrifugation at 13000 x g for 10 min at 4°C. Pellets were resuspended in 50 μl buffer E (20 mM Tris/HCl pH 7.9, 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol, 0.5 mM AEBSF, 1 mM Na3VO4, 1 mM Na2MoO4, 10 mM NaF, 20 mM glycerol-2-phosphate, phosphatase inhibitor tablet (Roche), 1 μl Benzonase Nuclease (25 U/μl, Novagen) and 2% SDS). After incubation for 30 min at 4°C with shaking N2 fractions were collected by centrifugation at 13000 x g for 10 min at 4°C.

### AQUA-Mass Spectrometry {#sec5.4.20}

Immunoprecipitates (sepharose beads) were suspended in 50 mM NH4HCO3 and cysteins were ß-thiomethylated by dithiothreitol reduction (1 mM DTT, 56°C, 45 min) and subsequent S-Methyl methanethiosulphonate (MMTS) treatment (5 mM MMTS, 30 min). Tryptic digestion was performed by addition of 0.5 μg Trypsin (Trypsin Gold, Promega) and incubated at 37°C for 24 h. AQUA peptides for caspase 8, FADD, c-Flip and RIPK1 were spiked into the digestion solution in an absolute amount of 50 fmol of each peptide as described previously ([@bib36]). Sequences of AQUA peptides could be received upon request. After digestion, the supernatant was collected and dried down in a vacuum centrifuge. The peptides were redissolved in 5 μl 0.1 % trifluoroacetic acid (TFA) and purified on ZIP-TIP, C18-nanocolumns (Millipore, Billerica, USA). Peptides were eluted in 7 μl 70% (v/v) acetonitrile (ACN) and subsequently dried in a vacuum centrifuge. Dried samples were dissolved in 10 μl 2% ACN/0.1% TFA and separated on a 75 μm I.D., 25 cm PepMap C18-column (Dionex, Sunnyvale, USA) applying a gradient from 2% to 45% ACN in 0.1% formic acid over 120 min at 300 nl/min using an Ultimate 3000 Nano-HPLC (Thermo Scientific, San Jose, USA). Mass spectrometry was performed on a hybrid dual-pressure linear ion trap/orbitrap mass spectrometer (LTQ Orbitrap Velos Pro, Thermo Scientific, San Jose, USA) in exclusive orbitrap full MS mode (FTMS; resolution 60,000; m/z range 400-2000). Instrument control, data acquisition and peak integration were performed using the Xcalibur software 2.2 (Thermo Fisher Scientific). Extracted ion chromatograms derived from Orbitrap mass scans from each AQUA/target peptide pair were generated and the peak areas of the light and heavy peptide were obtained by manual integration, respectively. The heavy to light ratio of each AQUA peptide pair was calculated and the resulting absolute amount of the endogenous (light) peptide was determined.

### Analysis of Data from Human Hepatocellular Carcinoma {#sec5.4.21}

Data mining was performed to assess the relevance of caspase 8 in HCC. All analyses were performed using the R statistical programming environment, version 3.2.2. Publicly available data from the Cancer Genome Atlas (TCGA) project were used. Clinical data and Level 3 RNA sequencing data were downloaded from the TCGA website (<https://tcga-data.nci.nih.gov/> -- files nationwidechildrens.org_LIHC.bio.Level_2.0.54.0 and unc.edu_LIHC.IlluminaHiSeq_RNASeqV2.Level_3.1.14.0, respectively). Methylation data were downloaded via cBioPortal (<http://www.cbioportal.org/>) using the cgdsr R package on 11^th^ November 2015. Patients with fibrolamellar hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma were excluded. The UPC (Universal exPression Codes) method, as implemented by the SCAN.UPC R/Bioconductor package ([@bib33]), was used to evaluate whether genes within the TCGA dataset should be considered to be expressed in individual patients (UPC values \> 0.5 indicating expression of the gene). Count data from RNA sequencing were transformed using the formula log2 (x + 1) to better approximate a normal distribution. Methylation data from cBioPortal were dichotomized using a percentage of methylation (β) cutoff of 0.3 (\< 0.3 unmethylated, \> 0.3 methylated). The log rank test was used to assess association with survival. For RNA expression, the median, the mean + 1 standard deviation (shown in the final figure), and the mean - 1 standard deviation were initially used as cutoffs to separate patients into two groups according to the level of CASP8 expression; the p value shown in the final figure was corrected for 3 tests using the Bonferroni method. Spearman's rank correlation coefficient was used to assess the correlation between genes.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

### Statistical Analysis {#sec5.5.1}

Statistical analysis was performed using GraphPad Prism software (version 5.0) or SPSS. All data are presented as mean ± SEM and were analyzed by ANOVA with Bonferroni correction. Analysis of two samples was performed with Student *t* test, statistics for HCC incidence were calculated using Fisher's Exact test. Statistical significance is indicated as follows: ^∗∗∗∗^*p* \< 0.0001; ^∗∗∗^*p* \< 0.001; ^∗∗^*p* \< 0.01; ^∗^*p* \< 0.05; n.s. not significant.

### Modelling of Mutation Rates Depending on Proliferative Activity {#sec5.5.2}

A rough calculation of the replication error rates depending on the replication rate in wild type mice and Mcl-1^Δhep^ mice with low transaminase levels and corresponding low proliferative activity or Mcl-1^Δhep^ mice with high transaminase levels and corresponding high proliferative activity. Modelling was based on proliferation rates determined by Ki67^+^ hepatocytes at 2 months of age revealing that Mcl-1^Δhep^ mice have about 10- to 25-fold higher Ki67 rates (see [Figure 2](#fig2){ref-type="fig"}). Calculation is based on the following assumptions: A wild type mouse liver weighting 2 g consists of ∼2x10^8^ hepatocytes, and assuming a proliferation index of 0.2 ([@bib12]), 4x10^5^ proliferating hepatocytes. Further, assuming an replication error rate of 10^-8^ per cell per generation ([@bib40]), and 24 h cycle duration ([@bib2]), taking Poisson distribution as basis, the expected number of replications errors after 1 year of is 1.46 for wild type mice, 14.6 for Mcl-1^Δhep^ mice with low hepatocyte proliferative activity, and 36.8 for Mcl-1^Δhep^ mice with high hepatocyte proliferative activity.

Data and Software Availability {#sec5.6}
------------------------------

Gene expression microarray data are deposited in the GEO database under accession number [GSE75730](ncbi-geo:GSE75730){#intref0125}.
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